Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation (Q38978057)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation |
scientific article |
Statements
1 reference
Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation (English)
1 reference
Naruo Yoshimura
1 reference
Shinzoh Kudoh
1 reference
Shigeki Mitsuoka
1 reference
Naoki Yoshimoto
1 reference
Takako Oka
1 reference
Toshiyuki Nakai
1 reference
Tomohiro Suzumira
1 reference
Kuniomi Matusura
1 reference
Yoshihiro Tochino
1 reference
Kazuhisa Asai
1 reference
Tatsuo Kimura
1 reference
Tomoya Kawaguchi
1 reference
Kazuto Hirata
1 reference
15 June 2015
1 reference
1 reference
90
1 reference
1
1 reference
65-70
1 reference
Identifiers
1 reference
1 reference